ProPhase Labs, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
ProPhase Labs, Inc. (PRPH) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$35.00 thousand for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-13.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2017-11-13
- 2017-09-30: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month -$35.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month |
|---|---|
| 2017-09-30 | -$35.00K 10-Q · filed 2017-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |